TP53 and acute myeloid leukemia: In a preliminary analysis of 45 TP53-mutated patients with myelodysplastic syndrome (MDS), a pre-leukemia state, and oligoblastic AML in a phase Ib/II combination study (APR-246 and azacitidine; NCT03072043) [124], the overall response rate (ORR) was 87% with 53% CR.